01—Abstract
Summary
Summary of the 8-K filed January 24, 2024. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. filed this Form 8-K under Item 5.02 to report a board change.
Effective January 22, 2024, the Board increased its size from eleven to twelve members and then filled the new vacancy by appointing Ms. Reshema Kemps-Polanco as a director. The filing states she has been appointed to the existing Compensation Committee and Strategic Planning and Capital Allocation Committee. The filing states there are no arrangements or understandings under which she was selected as a director, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
She will participate in the non-employee director compensation program. Under that program, the annual equity award before pro-rata adjustment is valued at $255,500,a split 50% restricted stock units and 50% stock options, issued on the first day of the month following her appointment. New directors appointed after the Annual Meeting also receive an initial equity award and cash retainer on a pro-rata basis.
Ms. Kemps-Polanco has 25 years of pharmaceutical industry experience and is currently Executive Vice President and Chief Commercial Officer of Novartis US. Her prior roles include several leadership positions at Johnson & Johnson from 2014 to 2021, and she began her career at Novartis in sales. For investors, the filing is primarily a governance update with a new independent director and no financial results disclosed.
02—Key points
Key Highlights
- Board size increased from eleven to twelve members, effective January 22, 2024
- Reshema Kemps-Polanco appointed to the Board to fill the newly created vacancy
- Appointed to the existing Compensation Committee and Strategic Planning and Capital Allocation Committee
- Annual non-employee director equity award (before pro-rata adjustment) valued at $255,500, split 50% RSUs and 50% stock options
- No arrangements or understandings for her selection and no Item 404(a) related-party transactions disclosed
- Director brings 25 years of pharmaceutical industry experience; currently EVP and Chief Commercial Officer of Novartis US
03—Questions
Frequently Asked Questions
Who was appointed to the Charles River Laboratories board?
Ms. Reshema Kemps-Polanco was appointed to the Board effective January 22, 2024, filling a vacancy created when the Board increased its size from eleven to twelve members.
What board committees will the new director serve on?
She was appointed to the existing Compensation Committee and the Strategic Planning and Capital Allocation Committee.
How will the new director be compensated?
She will participate in the non-employee director compensation program. The annual equity award, before pro-rata adjustment, is valued at $255,500 and is issued 50% as restricted stock units and 50% as stock options, on the first day of the month following appointment. New directors also receive an initial equity award and cash retainer on a pro-rata basis.
What is the new director's background?
She has 25 years of pharmaceutical industry experience and is currently Executive Vice President and Chief Commercial Officer of Novartis US, responsible for commercialization across oncology, immunology, neurology, and cardiovascular/renal/metabolic conditions. She previously held leadership roles at Johnson & Johnson from 2014 to 2021, including President of Janssen U.S. Cardiovascular & Metabolism, and began her career at Novartis in sales.
Are there any related-party transactions or undisclosed arrangements tied to the appointment?
The filing states there are no arrangements or understandings between Ms. Kemps-Polanco and any other person pursuant to which she was selected as director, and no transactions in which she has an interest requiring disclosure under Item 404(a) of Regulation S-K.
04—Continue